Page 287 - Read Online

30. Takada‑Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, neurons. Curr Alzheimer Res 2011;8:552‑62.
Akaike A. Acetylcholinesterase inhibitors used in treatment of 52. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and
Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic neurodegeneration. Pflugers Arch 2010;460:525‑42.
acetylcholine receptors and phosphatidylinositol 3‑kinase cascade. 53. O’Shea SD, Smith IM, McCabe OM, Cronin MM, Walsh DM,
Neuropharmacology 2006;51:474‑86. O’Connor WT. Intracerebroventricular administration of amyloid
31. Rubio‑Perez JM, Morillas‑Ruiz JM. A review: inflammatory process b‑protein oligomers selectively increases dorsal hippocampal
in Alzheimer’s disease, role of cytokines. ScientificWorldJournal dialysate glutamate levels in the awake rat. Sensors 2008;8:7428‑37.
2012;2012:756357. 54. Rusakov DA, Harrison E, Stewart MG. Synapses in hippocampus
32. Doens D, Fernandez PL. Microglia receptors and their implications in occupy only 1‑2% of cell membranes and are spaced less than
the response to amyloid beta for Alzheimer’s disease pathogenesis. half‑micron apart: a quantitative ultrastructural analysis with
J Neuroinflammation 2014;11:48. discussion of physiological implications. Neuropharmacology
33. Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti‑inflammatory 1998;37:513‑21.
action of donepezil ameliorates tau pathology, synaptic loss, and 55. Papouin T, Oliet SH. Organization, control and function of
neurodegeneration in a tauopathy mouse model. J Alzheimers Dis extrasynaptic NMDA receptors. Philos Trans R Soc Lond B Biol Sci
2010;22:295‑306. 2014;369:20130601.
34. Hwang J, Hwang H, Lee HW, Suk K. Microglia signaling as a target 56. Leveille F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O,
of donepezil. Neuropharmacology 2010;58:1122‑9. Buisson A. Neuronal viability is controlled by a functional relation
35. Kim HG, Moon M, Choi JG, Park G, Kim AJ, Hur J, Lee KT, Oh MS. between synaptic and extrasynaptic NMDA receptors. FASEB J
Donepezil inhibits the amyloid‑beta oligomer‑induced microglial 2008;22:4258‑71.
activation in vitro and in vivo. Neurotoxicology 2014;40:23‑32. 57. Mohs RC. The clinical syndrome of Alzheimer’s disease: aspects
36. van Maanen MA, Vervoordeldonk MJ, Tak PP. The cholinergic particularly relevant to clinical trials. Genes Brain Behav
anti‑inflammatory pathway: towards innovative treatment of 2005;4:129‑33.
rheumatoid arthritis. Nat Rev Rheumatol 2009;5:229‑32. 58. Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L.
37. Ghia JE, Blennerhassett P, Kumar‑Ondiveeran H, Verdu EF, Neurotransmitter deficits in behavioural and psychological symptoms
Collins SM. The vagus nerve: a tonic inhibitory influence of Alzheimer’s disease. Mech Ageing Dev 2006;127:158‑65.
associated with inflammatory bowel disease in a murine model. 59. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric
Gastroenterology 2006;131:1122‑30. symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry
38. Song XM, Li JG, Wang YL, Hu ZF, Zhou Q, Du ZH, Jia BH. The 1998;6:S64‑78.
protective effect of the cholinergic anti‑inflammatory pathway 60. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T,
against septic shock in rats. Shock 2008;30:468‑72. Francis PT. Cholinergic deficits contribute to behavioral disturbance
39. Leib C, Katus HA, Kaya Z. Cholinergic control of inflammation in in patients with dementia. Neurology 2000;55:1460‑7.
cardiovascular diseases. Trends Cardiovasc Med 2013;23:46‑51. 61. Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M,
40. Pohanka M, Snopkova S, Havlickova K, Bostik P, Sinkorova Z, Marien P, Somers N, Nagels G, Pickut BA, De Deyn PP. The
Fusek J, Kuca K, Pikula J. Macrophage‑assisted inflammation and dopaminergic neurotransmitter system is associated with aggression
pharmacological regulation of the cholinergic anti‑inflammatory and agitation in frontotemporal dementia. Neurochem Int
pathway. Curr Med Chem 2011;18:539‑51. 2008;52:1052‑60.
41. Ulloa L. The vagus nerve and the nicotinic anti‑inflammatory 62. Carrasco MM, Aguera L, Gil P, Morinigo A, Leon T. Safety and
pathway. Nat Rev Drug Discov 2005;4:673‑84. effectiveness of donepezil on behavioral symptoms in patients with
42. Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:333‑40.
acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in 63. Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, Hofmeister J,
Alzheimer’s disease patients. Neuropharmacology 2006;50:606‑13. Cleary JP, Anwyl R, Rowan MJ. Protection against Abeta‑mediated
43. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, rapid disruption of synaptic plasticity and memory by memantine.
Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S. Neurobiol Aging 2011;32:614‑23.
Galantamine‑induced amyloid‑{beta} clearance mediated via 64. Saab BJ, Luca RM, Yuen WB, Saab AM, Roder JC. Memantine
stimulation of microglial nicotinic acetylcholine receptors. J Biol affects cognitive flexibility in the Morris water maze. J Alzheimers
Chem 2010;285:40180‑91. Dis 2011;27:477‑82.
44. Conti E, Galimberti G, Tremolizzo L, Masetto A, Cereda D, Zanchi C, 65. Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW. Low
Piazza F, Casati M, Isella V, Appollonio I, Ferrarese C. Cholinesterase doses of memantine disrupt memory in adult rats. J Neurosci
inhibitor use is associated with increased plasma levels of anti‑Abeta 2006;26:3923‑32.
1‑42 antibodies in Alzheimer’s disease patients. Neurosci Lett 66. Neumeister KL, Riepe MW. Synergistic effects of antidementia drugs
2010;486:193‑6. on spatial learning and recall in the APP23 transgenic mouse model
45. Lannfelt L, Relkin NR, Siemers ER. Amyloid‑ss‑directed of Alzheimer’s disease. J Alzheimers Dis 2012;30:245‑51.
immunotherapy for Alzheimer’s disease. J Intern Med 67. Shearman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N,
2014;275:284‑95. Sershen H, Lajtha A. Changes in cerebral neurotransmitters
46. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. and metabolites induced by acute donepezil and memantine
J Neurochem 1984;42:1‑11. administrations: a microdialysis study. Brain Res Bull 2006;69:204‑13.
47. Bliss TV, Collingridge GL. A synaptic model of memory: long‑term 68. Drever BD, Anderson WG, Johnson H, O’Callaghan M, Seo S,
potentiation in the hippocampus. Nature 1993;361:31‑9. Choi DY, Riedel G, Platt B. Memantine acts as a cholinergic stimulant
48. Ho VM, Lee JA, Martin KC. The cell biology of synaptic plasticity. in the mouse hippocampus. J Alzheimers Dis 2007;12:319‑33.
Science 2011;334:623‑8. 69. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine
49. Morris RG. Long‑term potentiation and memory. Philos Trans R blocks alpha7* nicotinic acetylcholine receptors more potently
Soc Lond B Biol Sci 2003;358:643‑7. than n‑methyl‑D‑aspartate receptors in rat hippocampal neurons.
50. Jacob CP, Koutsilieri E, Bartl J, Neuen‑Jacob E, Arzberger T, J Pharmacol Exp Ther 2005;312:1195‑205.
Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E. 70. Ihalainen J, Sarajarvi T, Rasmusson D, Kemppainen S,
Alterations in expression of glutamatergic transporters and receptors Keski‑Rahkonen P, Lehtonen M, Banerjee PK, Semba K, Tanila H.
in sporadic Alzheimer’s disease. J Alzheimers Dis 2007;11:97‑116. Effects of memantine and donepezil on cortical and hippocampal
51. Brito‑Moreira J, Paula‑Lima AC, Bomfim TR, Oliveira FB, acetylcholine levels and object recognition memory in rats.
Sepulveda FJ, De Mello FG, Aguayo LG, Panizzutti R, Ferreira ST. Neuropharmacology 2011;61:891‑9.
Abeta oligomers induce glutamate release from hippocampal 71. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T,

278 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 279